



Clinical trial results:

A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when replacing standard combination therapy in HIV-infected patients with prolonged virological suppression. RALAM Study

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2014-003142-27 |
| Trial protocol | ES |
| Global end of trial date | 28 February 2017 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 05 April 2025 |
| First version publication date | 05 April 2025 |

Trial information

Trial identification

| | |
|-----------------------|-------|
| Sponsor protocol code | RALAM |
|-----------------------|-------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02284035 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Fundació Clinic per a la Recerca Biomédica |
| Sponsor organisation address | C/ Villarroel, 170, Barcelona, Spain, |
| Public contact | Judit Pich, CTU Clinic (Clinical Trial Unit), jpich@recerca.clinic.cat |
| Scientific contact | Dr. Esteban Martínez, Hospital Clínic, estebanm@clinic.cat |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 28 February 2017 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 28 February 2017 |
| Global end of trial reached? | Yes |
| Global end of trial date | 28 February 2017 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

Efficacy in virological suppression assessed with standard plasma HIV-1 RNA detection (limit of detection 37 copies/mL).

Protection of trial subjects:

Informed consent was obtained from all participants to ensure they understood the study's risks and benefits. A Data and Safety Monitoring Board (DSMB) periodically reviewed the study data for safety and efficacy. Comprehensive clinical assessments and regular laboratory tests were conducted at follow-up visits. Adverse events were monitored and reported promptly. Virological monitoring and treatment adherence assessments were performed to ensure participant well-being.

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 01 June 2015 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-----------|
| Country: Number of subjects enrolled | Spain: 75 |
| Worldwide total number of subjects | 75 |
| EEA total number of subjects | 75 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 75 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

All trial subjects were recruited at a single site in Spain: Hospital Clínic de Barcelona.

Recruitment period: 01-June-2015 to 01-December-2015

Pre-assignment

Screening details:

Screening visit: Conducted within 2-4 weeks prior to the study start. During this visit, written informed consent was obtained from each patient, and demographic data, medical history, complete physical examination, and laboratory tests (including hematology, biochemistry, and plasma viral load) were performed to confirm eligibility.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Baseline visit (randomization) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Group 1 (experimental) |

Arm description:

Study group: Raltegravir / 3TC (MK0518B)

| | |
|--|-----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | MK0518B (Raltegravir/3TC) |
| Investigational medicinal product code | ATC: J05AR16 |
| Other name | Dutrebis, Lamivudine, Raltegravir |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

MK0518B (Raltegravir/3TC): 300/150mg twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.

EFFICAC MESURMENTS: Plasma viral load (HIV-RNA) will be mesured at weeks 0, 4, 12 and 24. SAFETY ASSESSMENTS: at ech visit, a physical examination and a blood test will be performed.

| | |
|------------------|-------------------|
| Arm title | Group 2 (control) |
|------------------|-------------------|

Arm description:

Standard combination therapy (to continue current treatment).

| | |
|--|---|
| Arm type | Active comparator |
| Investigational medicinal product name | No investigational medicinal product assigned in this arm |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

All drug products included in the antiretroviral regimen will be part of the standard prescription and will be used according to the prescribing information. EFFICAC MESURMENTS: Plasma viral load (HIV-RNA) will be mesured at weeks 0, 4, 12 and 24. SAFETY ASSESSMENTS: at ech visit, a physical examination and a blood test will be performed.

| Number of subjects in period 1 | Group 1 (experimental) | Group 2 (control) |
|--------------------------------|---------------------------|-------------------|
| Started | 50 | 25 |
| Consent withdrawn by subject | 49 | 25 |
| Completed | 49 | 25 |
| Not completed | 1 | 0 |
| Consent withdrawn by subject | 1 | - |

Period 2

| | |
|------------------------------|-------------------------|
| Period 2 title | Week 4 |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Group 1 (experimental) |

Arm description:

Study group: Raltegravir / 3TC (MK0518B)

| | |
|--|-----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | MK0518B (Raltegravir/3TC) |
| Investigational medicinal product code | ATC: J05AR16 |
| Other name | Dutrebis, Lamivudine, Raltegravir |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

MK0518B (Raltegravir/3TC): 300/150mg twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.

EFFICAC MESURMENTS: Plasma viral load (HIV-RNA) will be mesured at weeks 0, 4, 12 and 24. SAFETY ASSESSMENTS: at ech visit, a physical examination and a blood test will be performed.

| | |
|------------------|-------------------|
| Arm title | Group 2 (control) |
|------------------|-------------------|

Arm description:

Standard combination therapy (to continue current treatment).

| | |
|--|---|
| Arm type | Active comparator |
| Investigational medicinal product name | No investigational medicinal product assigned in this arm |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

All drug products included in the antiretroviral regimen will be part of the standard prescription and will be used according to the prescribing information. EFFICAC MESURMENTS: Plasma viral load (HIV-RNA) will be mesured at weeks 0, 4, 12 and 24. SAFETY ASSESSMENTS: at ech visit, a physical examination and a blood test will be performed.

| Number of subjects in period 2 | Group 1 (experimental) | Group 2 (control) |
|--------------------------------|---------------------------|-------------------|
| Started | 49 | 25 |
| Completed | 49 | 21 |
| Not completed | 0 | 4 |
| Consent withdrawn by subject | - | 2 |
| Lost to follow-up | - | 1 |
| Lack of efficacy | - | 1 |

Period 3

| | |
|------------------------------|-------------------------|
| Period 3 title | Week 12 |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Group 1 (experimental) |

Arm description:

Study group: Raltegravir / 3TC (MK0518B)

| | |
|--|-----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | MK0518B (Raltegravir/3TC) |
| Investigational medicinal product code | ATC: J05AR16 |
| Other name | Dutrebis, Lamivudine, Raltegravir |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

MK0518B (Raltegravir/3TC): 300/150mg twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.

EFFICAC MESURMENTS: Plasma viral load (HIV-RNA) will be mesured at weeks 0, 4, 12 and 24. SAFETY ASSESSMENTS: at ech visit, a physical examination and a blood test will be performed.

| | |
|------------------|-------------------|
| Arm title | Group 2 (control) |
|------------------|-------------------|

Arm description:

Standard combination therapy (to continue current treatment).

| | |
|--|---|
| Arm type | Active comparator |
| Investigational medicinal product name | No investigational medicinal product assigned in this arm |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

All drug products included in the antiretroviral regimen will be part of the standard prescription and will be used according to the prescribing information. EFFICAC MESURMENTS: Plasma viral load (HIV-RNA) will be mesured at weeks 0, 4, 12 and 24. SAFETY ASSESSMENTS: at ech visit, a physical examination and a blood test will be performed.

| Number of subjects in period 3 | Group 1 (experimental) | Group 2 (control) |
|---------------------------------------|---------------------------|-------------------|
| Started | 49 | 21 |
| Completed | 48 | 20 |
| Not completed | 1 | 1 |
| Pregnancy | 1 | - |
| Lost to follow-up | - | 1 |

Period 4

| | |
|------------------------------|-------------------------|
| Period 4 title | Week 24 |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Group 1 (experimental) |

Arm description:

Study group: Raltegravir / 3TC (MK0518B)

| | |
|--|-----------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | MK0518B (Raltegravir/3TC) |
| Investigational medicinal product code | ATC: J05AR16 |
| Other name | Dutrebis, Lamivudine, Raltegravir |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

MK0518B (Raltegravir/3TC): 300/150mg twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.

EFFICAC MESURMENTS: Plasma viral load (HIV-RNA) will be mesured at weeks 0, 4, 12 and 24. SAFETY ASSESSMENTS: at ech visit, a physical examination and a blood test will be performed.

| | |
|------------------|-------------------|
| Arm title | Group 2 (control) |
|------------------|-------------------|

Arm description:

Standard combination therapy (to continue current treatment).

| | |
|--|---|
| Arm type | Active comparator |
| Investigational medicinal product name | No investigational medicinal product assigned in this arm |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Film-coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

All drug products included in the antiretroviral regimen will be part of the standard prescription and will be used according to the prescribing information. EFFICAC MESURMENTS: Plasma viral load (HIV-RNA)

will be measured at weeks 0, 4, 12 and 24. SAFETY ASSESSMENTS: at each visit, a physical examination and a blood test will be performed.

| Number of subjects in period 4 | Group 1 (experimental) | Group 2 (control) |
|---------------------------------------|---------------------------|-------------------|
| Started | 48 | 20 |
| Completed | 47 | 20 |
| Not completed | 1 | 0 |
| Physician decision | 1 | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|------------------------|
| Reporting group title | Group 1 (experimental) |
|-----------------------|------------------------|

Reporting group description:

Study group: Raltegravir / 3TC (MK0518B)

| | |
|-----------------------|-------------------|
| Reporting group title | Group 2 (control) |
|-----------------------|-------------------|

Reporting group description:

Standard combination therapy (to continue current treatment).

| Reporting group values | Group 1 (experimental) | Group 2 (control) | Total |
|---------------------------------------|---------------------------|-------------------|-------|
| Number of subjects | 50 | 25 | 75 |
| Age categorical Units: Subjects | | | |
| Adults > 18 years | 49 | 25 | 74 |
| Not recorded | 1 | 0 | 1 |
| Age continuous Units: years | | | |
| arithmetic mean | 50 | 50 | |
| standard deviation | ± 12 | ± 13 | - |
| Gender categorical Units: Subjects | | | |
| Female | 12 | 4 | 16 |
| Male | 37 | 21 | 58 |
| Not recorded | 1 | 0 | 1 |
| Risk group Units: Subjects | | | |
| Homosexual | 32 | 17 | 49 |
| Heterosexual | 13 | 7 | 20 |
| Other | 4 | 1 | 5 |
| Not recorded | 1 | 0 | 1 |
| Race Units: Subjects | | | |
| White | 46 | 23 | 69 |
| Afroamerican | 0 | 1 | 1 |
| Not recorded | 4 | 1 | 5 |
| Hispanic ethnicity Units: Subjects | | | |
| Yes | 35 | 18 | 53 |
| No | 9 | 2 | 11 |
| Not recorded | 6 | 5 | 11 |

End points

End points reporting groups

| | |
|---|------------------------|
| Reporting group title | Group 1 (experimental) |
| Reporting group description: | |
| Study group: Raltegravir / 3TC (MK0518B) | |
| Reporting group title | Group 2 (control) |
| Reporting group description: | |
| Standard combination therapy (to continue current treatment). | |
| Reporting group title | Group 1 (experimental) |
| Reporting group description: | |
| Study group: Raltegravir / 3TC (MK0518B) | |
| Reporting group title | Group 2 (control) |
| Reporting group description: | |
| Standard combination therapy (to continue current treatment). | |
| Reporting group title | Group 1 (experimental) |
| Reporting group description: | |
| Study group: Raltegravir / 3TC (MK0518B) | |
| Reporting group title | Group 2 (control) |
| Reporting group description: | |
| Standard combination therapy (to continue current treatment). | |
| Reporting group title | Group 1 (experimental) |
| Reporting group description: | |
| Study group: Raltegravir / 3TC (MK0518B) | |
| Reporting group title | Group 2 (control) |
| Reporting group description: | |
| Standard combination therapy (to continue current treatment). | |
| Reporting group title | Group 1 (experimental) |
| Reporting group description: | |
| Study group: Raltegravir / 3TC (MK0518B) | |
| Reporting group title | Group 2 (control) |
| Reporting group description: | |
| Standard combination therapy (to continue current treatment). | |

Primary: Proportion of patients free of therapeutic failure

| | |
|-------------------------|--|
| End point title | Proportion of patients free of therapeutic failure |
| End point description: | |
| On treatment population | |
| End point type | Primary |
| End point timeframe: | |
| 24 weeks | |

| End point values | Group 1 (experimental) | Group 2 (control) | | |
|-----------------------------|---------------------------|----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 48 | 23 | | |
| Units: Subjects | | | | |
| Yes | 47 | 20 | | |
| No | 1 | 3 | | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Statistical analysis |
| Comparison groups | Group 1 (experimental) v Group 2 (control) |
| Number of subjects included in analysis | 71 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| P-value | < 0.05 |
| Method | Newcombe method 10 |

Secondary: Proportion of patients with viral load below 37 copies/ml at 24 weeks

| | |
|------------------------|---|
| End point title | Proportion of patients with viral load below 37 copies/ml at 24 weeks |
| End point description: | |
| End point type | Secondary |
| End point timeframe: | |
| 24 weeks | |

| End point values | Group 1 (experimental) | Group 2 (control) | | |
|-----------------------------|---------------------------|----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 49 | 25 | | |
| Units: Subjects | | | | |
| Yes | 49 | 24 | | |
| No | 0 | 1 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Changes from baseline in metabolic parameters including fasting plasma lipids (cholesterol total)

| | |
|------------------------|---|
| End point title | Changes from baseline in metabolic parameters including fasting plasma lipids (cholesterol total) |
| End point description: | |
| End point type | Secondary |

End point timeframe:

24 weeks

| End point values | Group 1 (experimental) | Group 2 (control) | | |
|--|---------------------------|----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 49 | 25 | | |
| Units: mg/dL | | | | |
| least squares mean (confidence interval 95%) | 0.803 (-16.986 to 18.593) | -1.280 (-27.798 to 25.238) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence of adverse events in both treatment arms

| | |
|-----------------|--|
| End point title | Incidence of adverse events in both treatment arms |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 weeks

| End point values | Group 1 (experimental) | Group 2 (control) | | |
|---------------------------------|---------------------------|----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 49 | 25 | | |
| Units: Number of adverse events | | | | |
| Adverse events | 57 | 26 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Proportion of patients with serious adverse events related to study medication

| | |
|-----------------|--|
| End point title | Proportion of patients with serious adverse events related to study medication |
|-----------------|--|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 weeks

| End point values | Group 1 (experimental) | Group 2 (control) | | |
|-----------------------------|---------------------------|----------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 49 | 25 | | |
| Units: Subjects | | | | |
| Yes | 3 | 3 | | |
| No | 46 | 22 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Changes in treatment adherence during all the study duration (Morisky-Green test)

| | |
|-----------------|---|
| End point title | Changes in treatment adherence during all the study duration (Morisky-Green test) |
|-----------------|---|

End point description:

ODDS ratio and 95% confidence interval.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 weeks

| End point values | Group 1 (experimental) | Group 2 (control) | | |
|----------------------------------|---------------------------|-------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 48 | 24 | | |
| Units: Subjects | | | | |
| number (confidence interval 95%) | 1.074 (0.471 to 2.449) | 1.074 (0.903 to 12.130) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Changes from metabolic parameters including fasting plasma lipids (LDL) at 24 weeks

| | |
|-----------------|---|
| End point title | Changes from metabolic parameters including fasting plasma lipids (LDL) at 24 weeks |
|-----------------|---|

End point description:

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| 24 weeks | |

| End point values | Group 1 (experimental) | Group 2 (control) | | |
|--|----------------------------|---------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 44 | 22 | | |
| Units: mg/dl | | | | |
| least squares mean (confidence interval 95%) | -0.611 (-16.103 to 14.881) | 2.222 (-20.663 to 25.108) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Changes from baseline in metabolic parameters including fasting plasma lipids (HDL) at 24 weeks

| | |
|-----------------|---|
| End point title | Changes from baseline in metabolic parameters including fasting plasma lipids (HDL) at 24 weeks |
|-----------------|---|

End point description:

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| 24 weeks | |

| End point values | Group 1 (experimental) | Group 2 (control) | | |
|--|---------------------------|--------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 49 | 25 | | |
| Units: mg/dl | | | | |
| least squares mean (confidence interval 95%) | 1.158 (-4.530 to 6.845) | -0.099 (-8.578 to 8.380) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Changes from baseline in metabolic parameters including fasting plasma lipids (triglycerides) at 24 weeks

| | |
|-----------------|---|
| End point title | Changes from baseline in metabolic parameters including fasting plasma lipids (triglycerides) at 24 weeks |
|-----------------|---|

End point description:

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

24 weeks

| End point values | Group 1 (experimental) | Group 2 (control) | | |
|--|---------------------------|------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 49 | 25 | | |
| Units: mg/dl | | | | |
| least squares mean (confidence interval 95%) | 0.992 (0.822 to 1.196) | 0.901 (0.681 to 1.191) | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were reported throughout the entire study period, which spanned 24 weeks, with medical visits at weeks 4, 12, and 24.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|-------|
| Dictionary name | DAIDS |
|-----------------|-------|

| | |
|--------------------|-----|
| Dictionary version | 1.0 |
|--------------------|-----|

Reporting groups

| | |
|-----------------------|-----------------------------|
| Reporting group title | Continue previous treatment |
|-----------------------|-----------------------------|

Reporting group description:

Control group

| | |
|-----------------------|---------|
| Reporting group title | RAL/3TC |
|-----------------------|---------|

Reporting group description:

Experimental group. Raltegravir/ lamivudine.

| Serious adverse events | Continue previous treatment | RAL/3TC | |
|---|-----------------------------|----------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 3 / 25 (12.00%) | 3 / 49 (6.12%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | | | |
| Investigations | | | |
| Elevated LDH, CK, anemia, and thrombocytopenia | | | |
| subjects affected / exposed | 0 / 25 (0.00%) | 1 / 49 (2.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Neoplasm | | | |
| subjects affected / exposed | 1 / 25 (4.00%) | 1 / 49 (2.04%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Surgical and medical procedures | | | |
| Scheduled surgery | | | |
| subjects affected / exposed | 0 / 25 (0.00%) | 1 / 49 (2.04%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|----------------|----------------|--|
| General disorders and administration site conditions | | | |
| Constitutional syndrome, hilar adenopathy, and anemia study subjects affected / exposed | 1 / 25 (4.00%) | 0 / 49 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Episode of diarrhea subjects affected / exposed | 1 / 25 (4.00%) | 0 / 49 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Febrile syndrome subjects affected / exposed | 1 / 25 (4.00%) | 0 / 49 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Continue previous treatment | RAL/3TC | |
|---|-----------------------------|------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 16 / 25 (64.00%) | 32 / 49 (65.31%) | |
| Investigations | | | |
| Laboratory subjects affected / exposed | 5 / 25 (20.00%) | 3 / 49 (6.12%) | |
| occurrences (all) | 5 | 3 | |
| Cardiac disorders | | | |
| Cardiovascular subjects affected / exposed | 0 / 25 (0.00%) | 1 / 49 (2.04%) | |
| occurrences (all) | 0 | 1 | |
| Nervous system disorders | | | |
| Neurologic subjects affected / exposed | 4 / 25 (16.00%) | 5 / 49 (10.20%) | |
| occurrences (all) | 4 | 5 | |
| Pregnancy, puerperium and perinatal conditions | | | |

| | | | |
|---|----------------------|------------------------|--|
| Pregnancy subjects affected / exposed occurrences (all) | 0 / 25 (0.00%) 0 | 1 / 49 (2.04%) 1 | |
| General disorders and administration site conditions Systemic subjects affected / exposed occurrences (all) | 2 / 25 (8.00%) 2 | 0 / 49 (0.00%) 0 | |
| Eye disorders Ophtalmologic subjects affected / exposed occurrences (all) | 0 / 25 (0.00%) 0 | 3 / 49 (6.12%) 3 | |
| Gastrointestinal disorders Gastrointestinal subjects affected / exposed occurrences (all) | 2 / 25 (8.00%) 2 | 16 / 49 (32.65%) 16 | |
| Skin and subcutaneous tissue disorders Dermatologic subjects affected / exposed occurrences (all) | 2 / 25 (8.00%) 2 | 2 / 49 (4.08%) 2 | |
| Renal and urinary disorders Genitourinary subjects affected / exposed occurrences (all) | 0 / 25 (0.00%) 0 | 1 / 49 (2.04%) 1 | |
| Musculoskeletal and connective tissue disorders Muscular subjects affected / exposed occurrences (all) | 5 / 25 (20.00%) 5 | 14 / 49 (28.57%) 14 | |
| Infections and infestations Infection subjects affected / exposed occurrences (all) | 6 / 25 (24.00%) 6 | 12 / 49 (24.49%) 12 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 13 November 2014 | The objective of the amendment was to modify the change in the formulation of the investigational medicinal product. Amend the protocol version: Version 2.0 dated 7 November 2014. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/31335805>